AIDS research in Mali has begun

Naltrexone was developed in the sixties to help get drug addicts off drugs.  It had minimal side-effects, such as the possibility of sleep disturbances for the first two weeks of use. But more recently, doctors have found that the drug can help boost the immune system.

Dr. Jaquelyn McCandless found, in her research on autistic children, that when the drug was used it at one-tenth of the regular dose – called low-dose-Naltrexone – that the children’s health improved.  In her further reading she learned that for about twenty years Dr. Bihari in New York had used it for many patients with a lot of different diseases. He measured the CD4 counts for AIDS patients and was confident that this would be a great, cheap alternative drug for AIDS treatment.  Dr. McCandless felt it was necessary to do research for the treatment of AIDS patients.

Research world-wide is usually paid for by drug companies.  No drug company has interest in doing research on a cheap generic drug such as Naltrexone. However, using alternative funding over the past two years, research based on the preliminarily work of Dr. Bihari has begun.  In Pennsylvania, research on Chrome’s Disease, a disease of the bowel, has given two-thirds of the patients remission from their disease (see low-dose-Naltrexone.org). And just beginning is research at the University of San Francisco on Multiple Sclerosis (MS), while at Stanford research is being conducted with the drug on patients with fibromyalgia. There are many other auto-immune diseases that might be helped by a low dose of Naltrexone.

Dr. McCandless has just returned to her home in Hawaii from a trip to Mali, Africa, where she began the research on AIDS treatment with low-dose-Naltrexone. There 250 women who are HIV positive have been selected to participate in research on treatment for HIV.  One-third of the women will receive low-dose-Naltrexone, one third will receive the expensive HAART medications, and one-third will receive both sets of drugs.  All will be treated to attempt to keep their CD4 counts from dropping below 300, the marker for AIDS diagnosis.  Dr. McCandless is hoping that Naltrexone, a drug that might be produced in Africa for the Africans who are being decimated by AIDS, may be produced and marketed for $25 a year, a fraction of the cost of the high-priced first world medications.

For further information go to lowdosenaltrexone.org or lowdosenaltrexone.com and LDNAfricaAIDS.org.

Chatsworth Dental Group
21800 Devonshire Street Chatsworth, CA 91311 
818-709-1200